Lead team responsible for driving patient access and commercialization decisions including pricing, contracting (to secure insurance coverage), and distribution for Roche/Genentech’s product portfolio.Set direction for cross portfolio pricing, policy, patient access programs, and distribution strategies. Also own specific responsibility for Genentech’s ophthalmology portfolio of drugs and devices — including its most successful brand launch in its nearly 50 year history, Vabysmo.Considered the founder of the biotechnology industry, Genentech discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. Roche / Genentech spends more on R&D annually than any other healthcare company in the world.

Strategy lead responsible for patient access and commercialization decisions including pricing, contracting (insurance coverage), and distribution for Roche/Genentech’s Alzheimer's Disease pipeline and Neuroimmunology portfolio -- including the company's highest grossing brand in its history, Ocrevus ($5B+ annually).Served as subject matter expert for the biotech company’s cross-portfolio distribution strategy and channel customer (pharmacy, distributor) economics. Well-versed in industry implications stemming from the 2022 Inflation Reduction Act.

Managed patient access and commercialization strategy decisions for products for the company's:Alzheimer’s pipelineRespiratory portfolio (Mar 2021 to Nov 2021): • Xolair: the company’s 2nd largest brand at ~$2.5B in annual US sales • Esbriet: indicated for pulmonary fibrosis, a rare disease. $1B annual salesThrombolytics portfolio, Hemophilia franchise, and Neuroscience and rare blood disorder pipeline (Oct 2019 to Mar 2021): • Thrombolytics are clot-busting drugs (e.g., tPA) primarily used in the treatment of stroke and heart attack • The neuroscience pipeline includes potential Autism, Huntington's Disease, Parkinson's, and ALS drugs and digital therapeutic technologies (DTx)

Built a 15 person team responsible for articulating CVS Pharmacy’s growth strategy, assessing white space growth opportunities, and evaluating store format & real estate strategies.My team:• Created executive-level material articulating the business unit's growth strategy, the impact of trends (e.g., payer reimbursement pressure), and competitive threats• Assessed and executed on growth opportunities that expand patient care and/or yield new sources of revenue for the retail pharmacy business (e.g., build/buy/partner, digital investments, and product/market development)• Evaluated real estate opportunities (e.g., the acquisition of Schnucks' ~100 grocery store pharmacies)• Ran a center of excellence focused on maximizing patient retention in acquisitions of other pharmacies and winning new customers during disruptive market events• Conceptualized and launched a cross-functional initiative to deliver value across the enterprise (e.g., launched the nationwide sale of select over-the-counter items in the pharmacy drive-thru several months before COVID-19)At #4 on the Fortune 500, CVS Health is the largest healthcare company in the United States. It operates a retail pharmacy chain, health insurer (Aetna), pharmacy benefits manager aka PBM (Caremark), walk-in medical clinic (MinuteClinic), and long term care (Omnicare) and infusion services pharmacies (Coram).

Led a team responsible for articulating CVS Pharmacy's multi-year growth strategy. Conducted opportunity assessment, competitive intelligence, and acted as the 'voice of pharmacy' for enterprise initiatives.

Responsible for the definition and deployment of business-to-business growth initiatives for CVS Health's retail pharmacy businessFocus areas included:• Pharmacy network (PBM) configuration and planning• Medicare (Part D) / Seniors• Synergies related to CVS Health's ~$12B acquisition of Omnicare, a pharmacy services provider in the long-term care market

Conducted a cross-functional assessment to review the strategic and operational implications of innovative contracting (value-based contracting) efforts to align drug prices with value across the manufacturer’s product portfolio

Responsible for the definition and execution of healthcare services and initiatives for CVS' 7500+ stores. Managed and owned decisions for projects from ideation to execution: business case development, operational design, piloting, and implementation. Focused on partnership opportunities with hospitals and other healthcare providers.• Selected to lead the strategic analysis of and support the (DCF) valuation of a $200MM+ healthcare technology acquisition• Led strategic assessment of growth opportunities in 340B

Conducted analysis and developed strategic recommendations primarily for healthcare and life sciences clients.Functional Experience:• Growth strategy• Enterprise management reporting• Organizational restructuring• Process improvement and cost reductionIndustry Experience:• Healthcare / Life sciences (incl. pharmaceuticals, PBM, health insurance, medical devices, providers)• Consumer products• Financial servicesTechnical Experience:• Policy (Affordable Care Act aka "Health Reform/Obamacare" and HITECH Act)• Regulation (FDA Medical Device 510(k) Approval, Drug Risk Evaluation & Mitigation Strategies)• Pharmaceutical comparative effectiveness research• Pharmaceutical safety surveillanceDeloitte is the world's largest management consulting firm.